Successful Treatment of Refractory Gastrointestinal Bleeding by Systemic (Oral) Ankaferd Blood Stopper in a Patient with Glanzmann Thrombasthenia

Sibel Kabukçu Hacioğlu, Mehmet Hilmi Doğu, İsmail Sarı, Ali Keskin

Department of Hematology, Pamukkale University Faculty of Medicine, Denizli, Turkey

Background: Glanzmann Thrombasthenia (GT) is a genetic platelet dysfunction and a life threatening disease. Although it is a rare disease, it is the most common genetic platelet disorder. Symptoms and signs are mucosal and dermal petechia, recurring epistaxis and gastrointestinal (GI) bleeding and menorrhagia. Findings may be mild to life threatening in severity (1).

Ankaferd Blood Stopper (ABS) is a topical hemostatic agent of herbal origin which has been recently made available for clinical use. Its hemostatic effect is independent from blood clotting factors and occurs as a result of the aggregation of focal red blood cells by an encapsulated protein web.

Case Report: In this paper, a patient with GT is presented in whom 3 months of gastrointestinal bleeding refractory to all medical therapies was controlled within a short time of using oral ABS.

Conclusion: The difference between this patient and other cases presented in the medical literature is the oral use of ABS. Thus, this patient may contribute to the medical community in showing the safety and efficacy of systemic (oral) ABS in patients with disorders of coagulation. However, there is a need for more patient experiences.

Keywords: Ankaferd Blood Stopper, disorders of hemostasis, Glanzmann thrombasthenia, oral systemic administration

CASE PRESENTATION

A 29-year-old female patient was diagnosed with GT at 13 years of age. She did not experience a significant bleeding episode requiring medical intervention except menorrhagia until she was 24 years-old, at which time she was admitted to our clinic. Her diagnosis was confirmed with a history of mucosal bleeding, the existence of GT in her sister, and prolonged collagen-ADP and collagen epinephrine assays with Platelet Function Analyzer (PFA-100; Dade Behring, Marbourg, Germany). While her platelet counts were normal, the PFA and bleeding time were prolonged and no response was seen to all agonists except ristocetin by light transmission aggregometry (Chrono-log Whole-Blood Lumi-Aggregometer 560-CA with AGGRO/LINK® 5.1, Chrono-log Corp, Haverton, PA, USA). Surgical intervention for a diagnosis of endometriosis was performed with apheresis platelet suspension support, with-
out complications at that time. There was only one episode of menorrhagia 4 years ago which was unresponsive to antifibrinolytic and high dose progesterone treatment and apheresis platelet transfusions, and the menorrhagia was controlled with recombinant factor VIIa (rFVIIa). She was followed up for 4 years without any problem. Three months ago, she had taken non-steroidal anti-inflammatory drugs and was admitted to a different medical center due to dark stools. The GI system bleeding had continued in spite of all interventions, including apheresis platelet suspension, octostim, and rFVIIa, and then she was referred to our institution. Upon admission, her hemoglobin level was 7.1 g/dL, and platelet count was 320x10^9/L. Oral feeding was stopped; a proton pump inhibitor was given with the addition of daily apheresis platelet support. The origin of bleeding was not detected with GI endoscopic intervention. As the bleeding continued, supportive therapies such as tranexamic acid, vitamin K, and fresh frozen plasma were administered in addition to platelet and red blood cell replacements. Because the patient did not respond to any treatments, she was given rFVIIa on the 38th, 45th, and 58th days at a dose of 90 µg/kg, 3 times with 2 hour intervals, but bleeding could not be stopped. She was given ABS by oral administration at a dose of 3x4 mL because the origin of the bleeding had not been determined and owing to a life threatening reduction in hemoglobin levels in contrast with support of red blood cell transfusion. She gave informed consent before administration of the drug. The hemoglobin levels stabilized on the 3rd day and the stool color began to return to normal on the 5th day. This treatment was continued for 10 days. The bleeding symptoms disappeared and hemoglobin levels returned to normal at the end of the 10th day, and the patient began to be followed without treatment (Figure 1). The patient was administered a total of 70 units of apheresis platelets and 82 units of erythrocyte suspension during the 85 day process starting from the beginning of bleeding until the bleeding was controlled.

DISCUSSION

The bleeding episodes in GT are mostly mucosal bleeding, and the most frequent reasons for admittance to the hospital are gingival bleeding, epistaxis and serious menorrhagia (1). Unfortunately, treatment of patients with serious gastrointestinal bleeding as a life-threatening bleed is difficult. Bakdash et al. (5) could not control the bleeding in a 48-year-old female patient with endoscopic intervention, HLA-matched platelet transfusions and rFVIIa, and reported controlling the bleeding with partial gastrectomy after platelet transfusions and rFVIIa support. Bhat et al. (6) used rFVIIa in their patient with GT when the patient was 4-years-old for an upper gastrointestinal system bleed, and when the patient was 9-years-old for a lower GI system bleed; they reported improvement in bleeding in their study following their experience with rFVIIa in life-threatening bleeds.

Ankaferd Blood Stopper is a mixture of a number of herbs, and its effects on endothelial cells, blood cells, angiogenesis,
cell proliferation, vascular dynamics and/or mediators were shown. Its hemostatic effect is independent from blood clotting factors and occurs as a result of the aggregation of red blood cells by an encapsulated protein web (2). It has been used in Turkey in many clinical cases of bleeding in which conventional measures were not sufficient for control of the episode.

The success of ABS in patients with a normal hemostatic system was mostly shown for gastrointestinal bleeds (3) and dental applications (4). All of these applications were local administrations, with a median ABS amount of between 1 mL and 20-30 mL.

As the patient presented in this paper has a hemostasis defect, the medical literature on ABS applications in patients with a disorder of hemostasis was investigated, and more limited data were found. The activity of ABS was shown in 27 hemophilia A patients for the control of bleeding following tooth extraction (7) and in 4 patients with von Willebrand disease, chronic liver disease, and mitral valve replacement for the cessation of localized bleeding following dental procedures (8). Furthermore, the successful local application of ABS has been reported for massive hematuria in a hemodialysis patient complicated with disseminated intravascular coagulation (9), and upper gastrointestinal bleeding in a patient in whom a severe immune thrombocytopenia had developed (10).

In the first of several reports in the literature on its use in patients with GT is report of a 24-year-old patient in whom uncontrollable tooth gum bleeding during periodontal treatment was controlled by the local use of ABS (11). In the others, the efficacy of ABS was shown in oral cavity bleeding in 2 patients with GT, and in another 12 patients with hemophilia A or with other factor deficiencies (12).

In conclusion, ABS might be effective in patients with GT who have refractory GI bleeding. Another difference of this patient in comparison with other cases presented in the medical literature is the oral use of ABS. In only a few recent studies have high doses of oral ABS been reported to be safe in healthy rats (13) and tandem oral, rectal, and nasal administrations in patients with Klatkin tumor (14). Although this patient may contribute to the medical community in showing the safety and efficacy of systemic (oral) ABS in patients with disorders of hemostasis, it is obvious that further experience on its use in patients and further clinical studies are needed.

**Ethics Committee Approval:** N/A.

**Informed Consent:** Written informed consent was obtained from the patient.

**Peer-review:** Externally peer-reviewed.


**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**REFERENCES**